Ultraearly thrombolysis in acute ischemic stroke is associated with better outcome and lower mortality

Stroke

Volumn 41, Issue 4, 2010, Pages 712-716

  Strbian, Daniel ^a   Soinne, Lauri ^a   Sairanen, Tiina ^a   Häppölä, Olli ^a   Lindsberg, Perttu J ^a,b   Tatlisumak, Turgut ^a   Kaste, Markku ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Ischemic stroke; Outcome; Thrombolysis

Indexed keywords

ALTEPLASE; GLUCOSE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD CLOT LYSIS; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; GLUCOSE BLOOD LEVEL; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; PRIORITY JOURNAL; RANKIN SCALE; SYMPTOM; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MIDDLE AGED; PLACEBOS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77950235378     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.109.571976     Document Type: Article

References (17)

1. Hacke W Donnan G Fieschi C Kaste M von Kummer R Broderick JP Brott T Frankel M Grotta JC Haley EC Jr Kwiatkowski T Levine SR Lewandowski C Lu MLyden P Marler JR Patel S Tilley BC Albers GBluhmki E Wilhelm M Hamilton S. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS ECASS and NINDS rt-PA stroke trials. Lancet. 2004, 363, 768-774
2. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.
3. Wahlgren N, Ahmed N, Davalos A, Hacke W, Millan M, Muir K, Roine RO, Toni D, Lees KR; for the SITS investigators. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet. 2008;372:1303-1309.
4. Marler JR, Tilley BC, Lu M, Brott TG, Lyden PC, Grotta JC, Broderick JP, Levine SR, Frankel MP, Horowitz SH, Haley EC Jr, Lewandowski CA, Kwiatkowski TP. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology. 2000;55: 1649-1655.
5. Zivin JA, Fisher M, DeGirolami U, Hemenway CC, Stashak JA. Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science. 1985;230:1289-1292.
6. Zivin JA, Lyden PD, DeGirolami U, Kochhar A, Mazzarella V, Hemenway CC, Johnston P. Tissue plasminogen activator. Reduction of neurologic damage after experimental embolic stroke. Arch Neurol. 1988; 45:387-391.
7. Overgaard K. Thrombolytic therapy in experimental embolic stroke. Cerebrovasc Brain Metab Rev. 1994;6:257-286.
8. Engelter ST, Bonati LH, Lyrer PA. Intravenous thrombolysis in stroke patients of = 80 versus Intravenous thrombolysis in stroke patients of = 80 versus 80 years of age\a systematic review across cohort studies. Age Ageing. 2006, 35, 572-580
9. Mouradian MS, Senthilselvan A, Jickling G, McCombe JA, Emery DJ, Dean N, Shuaib A. Intravenous rt-PA for acute stroke: comparing its effectiveness in younger and older patients. J Neurol Neurosurg Psychiatry. 2005;76:1234-1237.
10. Tsivgoulis G, Saqqur M, Sharma VK, Lao AY, Hill MD, Alexandrov AV; for the CLOTBUST investigators. Association of pretreat-ment blood pressure with tissue plasminogen activator-induced arterial recanalization in acute ischemic stroke. Stroke. 2007;38: 961-966.
11. Brown DL, Johnston KC, Wagner DP, Haley EC Jr. Predicting major neurological improvement with intravenous recombinant tissue plasmin-ogen activator treatment of stroke. Stroke. 2004;35:147-150.
12. Saposnik G, Di Legge S, Webster F, Hachinski V. Predictors of major neurologic improvement after thrombolysis in acute stroke. Neurology. 2005;65:1169-1174.
13. Sobesky J, Frackowiak M, Zaro Weber O, Hahn M, Möller-Hartmann W, Rudolf J, Neveling M, Grond M, Schmulling S, Jacobs A, Heiss W-D. The Cologne stroke experience: safety and outcome in 450 patients treated with intravenous thrombolysis. Cerebrovasc Dis. 2007;24:56-65.
14. Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Kuelkens S, Larrue V, Lees KR, Roine RO, Soinne L, Toni D, Vanhooren G. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST): an observational study. Lancet. 2007; 369:275-282.
15. Loor HI, Groenier KH, Limburg M, Schuling J, Meyboom-de Jong B. Risks and causes of death in a community-based stroke population: 1 month and 3 years after stroke. Neuroepidemiology. 1999;18:75-84.
16. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA. 2000;283:1145-1150.
17. Lindsberg PJ, Häppölä O, Kallela M, Valanne L, Kuisma M, Kaste M. Door to thrombolysis: ER reorganization and reduced delays to acute stroke treatment. Neurology. 2006;67:334-336.